Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zynteglo Is Cost Effective At $2.1M, ICER Proposes; Validation For Bluebird’s Pivot To US?

Executive Summary

Draft evidence report from the Institute for Clinical and Economic Review on the potentially curative rare disease treatment also supports the narrative that the unrestricted pricing environment in the US invites greater access to innovative treatments compared to markets abroad. 

You may also be interested in...



Zynteglo Could Be Gene Therapy Test Case For Viability Of Outcomes-Based Contracts – UHC Exec

Outcomes and disease progression could be clear cut, lending the rare disease treatment to innovative contracting. But the amount of money at stake is likely to complicate things.

ICER Extends Influence Among US Insurers With AHIP Subscription Deal

AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.

Bluebird Bio Decision in Europe Is A Wake-Up Call For Payers and Industry

Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS146025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel